Document VjRvN6rJ8XdEJbBnk4oJD1G0q

/S THORflTRAST AMD A?niQ3A?.CC;t\ OF ..-g liver 1925-------Zgas Muniz 01 rra ice first wcncnoL*'--.ta J. a ruduo / active material in the form of colloidal Thorium dioxide could be used in cereoral vessel visualization. distribution in Europe and the United States for use vascular visualization-artenograpry-hepatospicnograpiy- and cerebral graphy. 1932- - The Council of Pharmacy of the American. Medical Association took a stand against its use. 1940- -Thorntrast was still in use although animal experimentation . . ' d/vfiiffns had demonstrated the formation* of c.irrrinomnn and in the livery angiosarcomas. 1947- -Finally discontinued when the human cases of angiosarcomas l$ere reported. -* * / It was K.H. Bauer of Germany who compared the time of appearance of neoplasms after the injection of tharotrast, experimentally 1 I produced in animals, with their average life expectancy and the average span of life in man. Ee came to the conclusion that such tumors ^sould appear between the 12th and the 18th year after the injection into the vascular system of naa. -C~^c ^Gae/r) I947----Endothelial Cell Sarcoma of the Liver following hn Thoratrast Injection. tecMahan, E.S., Murphy, A.S., and Bates, M. I. American Journal of Pathology ' 23: 535--611. The first case of angiosarcoma from thoratrast was reported in the U.S Jl. The latent period was 17 years. 1961------Neoplasms of the Liver following Injection of Thoratrast. Nettleship, A., and Fink, W. J. Am. Journal of Clinical Pathology Vol 35: 422--426. .' This was the 8th reported case of anjiosarcoma of the liver due to thoratrast. The latency pcricd was 16 years, 1` 1s r DTH 0000177qo